Edgestream Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Edgestream Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,671	Closed	-$374K	–	1025
2023 Q2	$374K	Sell	3,671 -8,679	-70%	-$821K	0.03%	592
2023 Q1	$1.12M	Sell	12,350 -27,488	-69%	-$1.61M	0.12%	275
2022 Q4	$1.51M	Sell	39,838 -41,922	-51%	-$1.44M	0.17%	196
2022 Q3	$2.06M	Buy	+81,760	New	+$2.27M	0.16%	190

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Edgestream Partners's RETA Position: Q3 2023 in Review

Edgestream Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,671 shares — an estimated $374K sold.

Edgestream Partners first reported a position in RETA in Q3 2022 and held it in 4 quarters. The position peaked at $2.06M in Q3 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Edgestream Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Edgestream Partners sold 3,671 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $374K.
Edgestream Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2022 and held it in 4 quarters.
Edgestream Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.06M in Q3 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Edgestream Partners's 13F filing for Q3 2023, filed 15 Nov 2023.